Literature DB >> 14581684

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

G J Groeneveld1, H J M Van Kan, S Kalmijn, J H Veldink, H-J Guchelaar, J H J Wokke, L H Van den Berg.   

Abstract

Riluzole exerts a dose-dependent effect on survival of patients with ALS and, although serum levels show a high interindividual variability, is usually prescribed in a fixed dose. In this study, riluzole serum levels and area under the curve per kilogram of body weight (AUC/kg) of 169 patients with ALS showed a high interindividual variability. Patients with high serum levels and AUC/kg more often had diarrhea but less often had fasciculations and muscle stiffness. It may therefore be advantageous to raise the riluzole dose in patients with low riluzole serum concentrations without the risk of serious side effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581684     DOI: 10.1212/01.wnl.0000090459.76784.49

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

Authors:  Chadi Abbara; Brigitte Estournet; Lucette Lacomblez; Benedicte Lelièvre; Amal Ouslimani; Blandine Lehmann; Louis Viollet; Annie Barois; Bertrand Diquet
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 2.  Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.

Authors:  Peter J Adhihetty; M Flint Beal
Journal:  Neuromolecular Med       Date:  2008-11-13       Impact factor: 3.843

3.  Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current.

Authors:  S Weiss; D Benoist; E White; W Teng; D A Saint
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 4.  Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.

Authors:  Ranjeet Prasad Dash; R Jayachandra Babu; Nuggehally R Srinivas
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

5.  Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.

Authors:  Mark E McDonnell; Matthew D Vera; Benjamin E Blass; Jeffrey C Pelletier; Richard C King; Carmen Fernandez-Metzler; Garry R Smith; Jay Wrobel; Suzie Chen; Brian A Wall; Allen B Reitz
Journal:  Bioorg Med Chem       Date:  2012-07-21       Impact factor: 3.641

6.  Dipeptide Prodrugs of the Glutamate Modulator Riluzole.

Authors:  Jeffrey C Pelletier; Suzie Chen; Haiyan Bian; Raj Shah; Garry R Smith; Jay E Wrobel; Allen B Reitz
Journal:  ACS Med Chem Lett       Date:  2018-06-15       Impact factor: 4.345

7.  Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.

Authors:  H J M van Kan; G J Groeneveld; S Kalmijn; M Spieksma; L H van den Berg; H J Guchelaar
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

8.  Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.

Authors:  Amber Cardoos; Aya Inamori; Gerard Sanacora; Maurizio Fava; David Mischoulon
Journal:  Psychosomatics       Date:  2013-03-06       Impact factor: 2.386

9.  A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.

Authors:  Dana Yip; Maithao N Le; Joseph L-K Chan; Jonathan H Lee; Janice A Mehnert; Anthony Yudd; Jeffery Kempf; Weichung J Shih; Suzie Chen; James S Goydos
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

Review 10.  Riluzole in psychiatry: a systematic review of the literature.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-09       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.